{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=36",
    "query": {
      "condition": "Randomized Controlled Study",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 15129,
    "total_pages": 1513,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T10:00:09.688Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02658435",
      "title": "Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Matched placebo 150mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 486,
      "start_date": "2016-02-02",
      "completion_date": "2017-09-14",
      "has_results": false,
      "last_update_posted_date": "2018-03-01",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 3,
      "location_summary": "Glendale, California • Overland Park, Kansas • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658435"
    },
    {
      "nct_id": "NCT00398125",
      "title": "Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "GSK364735",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-11",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398125"
    },
    {
      "nct_id": "NCT01613040",
      "title": "A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "RO4917838",
          "type": "DRUG"
        },
        {
          "name": "RO4917838 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 169,
      "start_date": "2009-01",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01613040"
    },
    {
      "nct_id": "NCT00156689",
      "title": "A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Idiopathic Axonal Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "levetiracetam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2005-08",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2008-01-11",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00156689"
    },
    {
      "nct_id": "NCT02636868",
      "title": "The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Lucinactant delivered via investigational delivery device",
          "type": "DRUG"
        },
        {
          "name": "nCPAP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Windtree Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "26 Weeks",
        "maximum_age": "32 Weeks",
        "sex": "ALL",
        "summary": "26 Weeks to 32 Weeks"
      },
      "enrollment_count": 221,
      "start_date": "2015-12",
      "completion_date": "2019-08-06",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02636868"
    },
    {
      "nct_id": "NCT02442778",
      "title": "Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation in Participants With Dementia of the Alzheimer's Type"
      ],
      "interventions": [
        {
          "name": "AVP-786-18",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-28",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-42.63",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 522,
      "start_date": "2015-11-11",
      "completion_date": "2019-09-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-09",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 79,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02442778"
    },
    {
      "nct_id": "NCT00043758",
      "title": "Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Tolvaptan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2002-07",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 35,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00043758"
    },
    {
      "nct_id": "NCT05108558",
      "title": "Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peyronie's Disease"
      ],
      "interventions": [
        {
          "name": "CCH administration",
          "type": "DRUG"
        },
        {
          "name": "Control - Crossover to CCH",
          "type": "DRUG"
        },
        {
          "name": "RestoreX",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Charitable Union for the Research and Education of Peyronie's Disease",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2021-09-20",
      "completion_date": "2026-06-13",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 1,
      "location_summary": "Orem, Utah",
      "locations": [
        {
          "city": "Orem",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05108558"
    },
    {
      "nct_id": "NCT01083615",
      "title": "A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Castrate-Resistant Prostate Cancer",
        "Hormone Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "custirsen sodium",
          "type": "DRUG"
        },
        {
          "name": "isotonic, 0.9% sodium chloride",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Achieve Life Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2010-03",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2016-10-12",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 20,
      "location_summary": "La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more",
      "locations": [
        {
          "city": "La Verne",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01083615"
    },
    {
      "nct_id": "NCT06441318",
      "title": "A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Povorcitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 128,
      "start_date": "2024-07-12",
      "completion_date": "2024-09-10",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-10-24T10:00:09.688Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06441318"
    }
  ]
}